HYD Pharma to test a new cancer drug
Hungarian pharmaceutical company HYD Pharma has just completed a HUF 250 mln research phase in the development of a new drug for cancer patients, Hungarian news agency MTI reported today. The company’s research and development unit has succeeded in producing a drug which contains deuterium-depleted water or DDW.
Deuterium-depletet water is known to mitigate the damaging effects of chemotherapy and radiation such as nausea, pain or hair loss.
The company will now proceed with clinical tests, the cost of which could reach a nine-figure range, HYD Pharma’s CEO said.
Venture capital fund manager Primus Capital recently invested HUF 400 mln in the pharmaceutical company. HYD Pharma’s net revenue totalled HUF 693 mln in 2013.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.